Notice of Intent to Publish a Funding Opportunity Announcement for Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)

0
104

Opportunity ID:333331
Opportunity Number:NOT-CA-21-068
Opportunity Title:Notice of Intent to Publish a Funding Opportunity Announcement for Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)
Opportunity Category:Discretionary
Opportunity Category Explanation:
Funding Instrument Type:Cooperative Agreement
Category of Funding Activity:Health
Category Explanation:
CFDA Number(s):93.393
93.394
93.395
93.396
93.399
Eligible Applicants:State governments
Public and State controlled institutions of higher education
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
For profit organizations other than small businesses
Small businesses
Additional Information on Eligibility:
Agency Code:HHS-NIH11
Agency Name:Department of Health and Human Services
National Institutes of Health
Posted Date:May 04, 2021
Last Updated Date:May 04, 2021
Estimated Synopsis Post Date:Jul 05, 2021
Fiscal Year:2022
Award Ceiling:$570,000
Award Floor:
Estimated Total Program Funding:$2,850,000
Expected Number of Awards:5
Description:The purpose of this Notice is to announce the NCI's intention to issue a Funding Opportunity Announcement (FOA) that invites applications for Canine Cancer Immunotherapy Network (K9CIN). Canine patients with spontaneous tumors closely mimic human conditions and physiology for preclinical immunotherapy research. The network of laboratories and canine clinical trial sites created through this FOA will support canine clinical studies using immunotherapeutic agents and novel drug combinations together with laboratory correlative studies that seek to characterize and understand the cellular and molecular mechanisms that determine anti-tumor responses (or non-responses) in pet dogs with spontaneous tumors. An essential goal of these studies will be to determine whether or not canine cancer is a close model of human malignant disease, and if so, whether immunotherapy alone or in combination with other modalities in canine models will inform the design of therapies in humans. This Notice is being provided to allow potential applicants sufficient time to develop a responsive grant application. The FOA is expected to be published in July 2021 with an expected application due date in October 2021. Details of a planned pre-application webinar will be announced in the Guide after the publication of the FOA. The FOA will utilize the U01 (Research Project-Cooperative Agreements) mechanism to support a network of laboratories and canine clinical trial sites. Within the network, awardees are expected to share therapeutic agents, specimens, and laboratory and clinical protocols in order to standardize and validate the data generated. A companion U24 funding opportunity will support a coordinating center that will aid in the development, standardization, harmonization, and conduct of the clinical and laboratory studies, as well as data management and statistical support across the funded U01 sites. Collectively, data generated through the funding announcement will assess the suitability of canine models to study single and combination immunomodulating agents, ideally with molecularly targeted drugs, chemotherapy, or radiation, for the purpose of translating the canine findings to human studies.
Version:1





Visit the Official Webpage For More Details on Notice of Intent to Publish a Funding Opportunity Announcement for Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)

LEAVE A REPLY

Please enter your comment!
Please enter your name here